129 related articles for article (PubMed ID: 2571672)
1. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
[TBL] [Abstract][Full Text] [Related]
2. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
Chang WH; Chen TY; Lin SK; Lung FW; Lin WL; Hu WH; Yeh EK
Biol Psychiatry; 1990 Mar; 27(5):510-8. PubMed ID: 2310806
[TBL] [Abstract][Full Text] [Related]
3. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
4. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
5. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
[TBL] [Abstract][Full Text] [Related]
6. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
7. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
[TBL] [Abstract][Full Text] [Related]
9. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
[TBL] [Abstract][Full Text] [Related]
10. Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients.
Zumárraga M; Dávila R; González-Torres MA; Anguiano JB; Zabalo MJ; Basterreche N; Arrúe A; Zamalloa MI; Guimón J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):713-9. PubMed ID: 17291661
[TBL] [Abstract][Full Text] [Related]
11. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine.
Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
Psychiatry Res; 1997 Mar; 69(2-3):113-21. PubMed ID: 9109179
[TBL] [Abstract][Full Text] [Related]
12. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
[TBL] [Abstract][Full Text] [Related]
13. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
[TBL] [Abstract][Full Text] [Related]
14. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
[TBL] [Abstract][Full Text] [Related]
15. Measurement of plasma homovanillic acid concentrations in schizophrenic patients.
Kaminski R; Powchick P; Warne PA; Goldstein M; McQueeney RT; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(3):271-87. PubMed ID: 2193315
[TBL] [Abstract][Full Text] [Related]
16. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
17. Plasma HVA in psychiatric patients: longitudinal studies.
Javaid JI; Sharma RP; Janicak PG; Davis JM
Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period.
Sharma RP; Javaid JI; Davis JM; Janicak PG
Biol Psychiatry; 1998 Sep; 44(6):488-92. PubMed ID: 9777181
[TBL] [Abstract][Full Text] [Related]
19. Plasma homovanillic acid levels and subtyping of schizophrenia.
Chang WH; Chen TY; Lee CF; Hung JC; Hu WH; Yeh EK
Psychiatry Res; 1988 Mar; 23(3):239-44. PubMed ID: 3387499
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
Garver DL; Holcomb JA; Christensen JD
J Clin Psychiatry; 2000 Dec; 61(12):964-72; quiz 973. PubMed ID: 11206608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
